Assembly Biosciences reported its financial results for the year ended December 31, 2024, with revenue reaching US$28.5 million. This represents a substantial increase of 298% compared to the previous fiscal year.
The company highlighted that four development candidates are currently in clinical studies, with data anticipated throughout 2025. This rapid progress across its antiviral pipeline reinforces the company's commitment to advancing novel therapeutics.
Interim Phase 1b proof-of-concept data, including initial efficacy measures, are expected in fall 2025 for ABI-5366 and ABI-1179, which are long-acting helicase-primase inhibitor candidates for recurrent genital herpes. These milestones are crucial for demonstrating the value of Assembly Bio's R&D efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.